Skip to main content

Advertisement

Table 2 Pharmacokinetic parameters of SLN-PZQ vs market PZQ at a single dose of 500 mg/kg

From: A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

Animal group Treatment Pharmacokinetic parameters (mean ± SEM)
ka (h−1) kel (h−1) t1/2e (h−1) AUC (μg h/ml) Cmax (μg/ml) Tmax (h)
Normal M-PZQ 6.52 ± 0.05 1.27 ± 0.01 0.55 ± 0.00 14.03 ± 0.98 15.98 ± 1.46 0.14 ± 0.04
SLN-PZQ 13.98 ± 1.30* 0.22 ± 0.03* 3.53 ± 0.60* 123.75 ± 11.39* 37.24 ± 2.07* 0.29 ± 0.04
S. mansoni-infected M-PZQ 11.23 ± 0.86$ 0.63 ± 0.01 1.11 ± 0.02 34.61 ± 2.50 24.31 ± 1.19 0.14 ± 0.04
SLN-PZQ 22.34 ± 0.67#† 0.10 ± 0.01#† 6.85 ± 0.60#† 286.33 ± 13.54#† 64.29 ± 7.78#† 0.22 ± 0.03
  1. * Significant differences between SLN-PZQ and M-PZQ in normal treated mice at P < 0.05
  2. #Significant differences between SLN-PZQ and M-PZQ in S. mansoni-infected treated mice at P < 0.05
  3. Significant differences of SLN-PZQ or M-PZQ in S. mansoni-infected mice compared to respective normal mice at P < 0.05
  4. Abbreviations: ka, absorption rate constant; kel, elimination rate constant; t1/2e, half-life of elimination; AUC, area under concentration-time curve; Cmax, maximum concentration; Tmax, time to reach Cmax; SLN-PZQ, solid lipid nanoparticle praziquantel; M-PZQ, market praziquantel